This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takebayashi, K. Articles by Inukai, T. Search for Related Content PubMed PubMed Citation Articles by Takebayashi, K. Articles by Inukai, T. Related Collections Diabetes and Insulin

Aldosterone Blockade Attenuates Urinary Monocyte Chemoattractant Protein-1 and Oxidative Stress in Patients with Type 2 Diabetes Complicated by Diabetic Nephropathy

Department of Internal Medicine, Koshigaya Hospital, Dokkyo University School of Medicine, Koshigaya 343-8555, Japan

Address all correspondence and requests for reprints to: Kohzo Takebayashi, M.D., Department of Internal Medicine, Koshigaya Hospital, Dokkyo University School of Medicine, 2-1-50, Minami-Koshigaya, Koshigaya 343-8555, Japan. E-mail: takeb{at}gmail.plala.or.jp.

Context: Aldosterone causes organic impairment by enhancement of oxidative stress and subsequent induction of proinflammatory cytokines and chemokines.

Objective: This study was designed to investigate the effect of spironolactone, an aldosterone blocker, on oxidative stress and the level of urinary monocyte chemoattractant protein (MCP)-1, a cysteine-cysteine chemokine that may contribute to progression of various nephropathies in type 2 diabetic patients with diabetic nephropathy.

Design, Setting, Patients and Other Participants, and Intervention: The patients were randomly assigned to two groups in which they received either spironolactone (50 mg/d; n = 23) or amlodipine (2.5 mg/d; n = 14).

Main Outcome Measures: Urinary 8-iso-prostaglandin (PG) F2 (a marker of oxidative stress), urinary MCP-1, and urinary albumin excretion (UAE) were measured at the start of administration (0 months) and after 3 months in each group. Baseline levels of these variables were also measured in 25 age-matched healthy subjects.

Results: There were significant positive correlations between log₁₀-transformed (log) 8-iso-PGF2 and log MCP-1 levels in control and diabetic subjects and all subjects combined, but no correlations between log UAE and log 8-iso-PGF2 or log MCP-1 were found in any group. Significant decreases in 8-iso-PGF2, MCP-1, and UAE were observed with spironolactone (P = 0.0001, P = 0.0041, and P = 0.0037, respectively), and systolic blood pressure significantly decreased after both spironolactone and amlodipine therapy (P = 0.00011 and P = 0.0051, respectively).

Conclusions: Our data suggest that urinary MCP-1 is correlated with oxidative stress as measured by urinary 8-iso-PGF2 and that spironolactone can decrease urinary MCP-1 and oxidative stress.

This article has been cited by other articles:

				Y. Jeong, D. F. Chaupin, K. Matsushita, M. Yamakuchi, S. J. Cameron, C. N. Morrell, and C. J. Lowenstein Aldosterone activates endothelial exocytosis PNAS, March 10, 2009; 106(10): 3782 - 3787. [Abstract] [Full Text] [PDF]

				Y. S. Kang, G. J. Ko, M. H. Lee, H. K. Song, S. Y. Han, K. H. Han, H. K. Kim, J. Y. Han, and D. R. Cha Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats Nephrol. Dial. Transplant., January 1, 2009; 24(1): 73 - 84. [Abstract] [Full Text] [PDF]

				N. J. Brown Salt in the Wound J. Am. Soc. Nephrol., January 1, 2009; 20(1): 5 - 6. [Full Text] [PDF]

				C. Guo, V. Ricchiuti, B. Q. Lian, T. M. Yao, P. Coutinho, J. R. Romero, J. Li, G. H. Williams, and G. K. Adler Mineralocorticoid Receptor Blockade Reverses Obesity-Related Changes in Expression of Adiponectin, Peroxisome Proliferator-Activated Receptor-{gamma}, and Proinflammatory Adipokines Circulation, April 29, 2008; 117(17): 2253 - 2261. [Abstract] [Full Text] [PDF]

				J. M. C. Connell, S. M. MacKenzie, E. M. Freel, R. Fraser, and E. Davies A Lifetime of Aldosterone Excess: Long-Term Consequences of Altered Regulation of Aldosterone Production for Cardiovascular Function Endocr. Rev., April 1, 2008; 29(2): 133 - 154. [Abstract] [Full Text] [PDF]

				G. H. Tesch MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy Am J Physiol Renal Physiol, April 1, 2008; 294(4): F697 - F701. [Abstract] [Full Text] [PDF]

				J. F. Navarro-Gonzalez and C. Mora-Fernandez The Role of Inflammatory Cytokines in Diabetic Nephropathy J. Am. Soc. Nephrol., March 1, 2008; 19(3): 433 - 442. [Abstract] [Full Text] [PDF]

				N. J. Brown Aldosterone and Vascular Inflammation Hypertension, February 1, 2008; 51(2): 161 - 167. [Full Text] [PDF]

				Jun Yuan, Ruhan Jia, and Yan Bao Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats Journal of Renin-Angiotensin-Aldosterone System, September 1, 2007; 8(3): 118 - 126. [Abstract] [PDF]

				K. Takebayashi, M. Suetsugu, S. Wakabayashi, Y. Aso, and T. Inukai Retinol Binding Protein-4 Levels and Clinical Features of Type 2 Diabetes Patients J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2712 - 2719. [Abstract] [Full Text] [PDF]